Skip To Main Content
Arnaud Boyer on Muck Rack

Arnaud Boyer

As seen in: Nature, European Respiratory Review
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Arnaud Boyer’s profile

Articles by Arnaud Boyer

Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial

|
By Martin Reck, Ernest Nadal, Carl M Gay, Nicolas Girard, Andrea Riccardo Filippi, Linda Martin, Cordula Petersen, David Cairns, Margarita Majem, Andrea Ardizzoni, Rosa Alvarez, Andrew Robinson, Benoît Roch, Arnaud Boyer, Ilaria Attili, Maximilian Diehn, Ignacio Pérez, Matteo Giaj Levra, Davina Gale, Zhou Zhu, Jonathan Spicer Verified, Ugochinyere A. Emeribe, Nefeli Georgoulia
| Nature Verified
Abstract The phase 2 MDT-BRIDGE study is investigating perioperative durvalumab plus neoadjuvant chemotherapy (AEGEAN regimen) in resectable and borderline resectable non-small-cell lung cancer and chemoradiotherapy (CRT) followed by consolidation durvalumab (PACIFIC regimen) in patients who become unresectable after neoadjuvant chemoimmunotherapy guided by multidisciplinary team assessments during the neoadjuvant period.
Open in Who Shared Issue with article?

Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?

|
By Aix Marseille, Multidisciplinary Oncology, Therapeutic Innovations Dept, Arnaud Boyer
| European Respiratory Review Verified
The concept of drug repurposingThe aim of drug repurposing is to identify and develop new indications for approved drugs [1, 2]. In oncology, drug repositioning consists of demonstrating the anticancer properties of marketed drugs approved for nonmalignant diseases [3]. Because repositioned drugs have well-known safety and pharmacokinetic profiles, faster development can be expected. Indeed, clinical development can start directly with phase II trials to assess the efficacy of the drug.
Open in Who Shared Issue with article?
Show More